GPT and congenital rubella syndrome: Four patients (10.3%) experienced one or more DLTs, and all of them experienced a CRS event before the DLTs: (i) Hypertransaminasemia (grade 3; JNJ-78306358 15-90-270 ug SC QW cohort), (ii) Recurrent CRS (grade 2 followed by grade 1, requiring dose reduction; JNJ-78306358 15-90-270 ug SC QW cohort), (iii) Increased ALT (grade 3; JNJ-78306358 15-46-270 ug SC QW cohort), and (iv) Pneumonitis (grade 3; JNJ-78306358 15-46-180 ug SC QW cohort).